Literature DB >> 3873280

Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method.

D C Lynch, T S Zimmerman, C J Collins, M Brown, M J Morin, E H Ling, D M Livingston.   

Abstract

We have identified a 2.4 kb partial cDNA clone (pDL34) for human von Willebrand factor (vWf) mRNA. pDL34 was selected by screening an endothelial cell cDNA library with a radiolabeled reverse transcript of mRNA obtained by specific immunoisolation of vWf polysomes from endothelial cells. pDL34 selectively hybridized to an endothelial cell-associated 9.5 kb mRNA. To confirm its identity, SP6 RNA polymerase was used to generate in vitro transcripts of the cDNA. This synthetic RNA, truncated at its 5' end, directed the synthesis of several unique polypeptides in rabbit reticulocyte lysates. These polypeptides were immunoprecipitated by polyclonal and monoclonal anti-vWf antibodies. These results indicate that pDL34 contains an authentic partial copy of vWf mRNA. In vitro transcription of partial cDNA clones and translation of the resulting RNAs may be a useful general method of verifying the identity of various cDNA clones in circumstances where antibodies are available and protein sequence is not.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873280     DOI: 10.1016/0092-8674(85)90060-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  34 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 2.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

Review 3.  Role of von Willebrand factor in the haemostasis.

Authors:  Flora Peyvandi; Isabella Garagiola; Luciano Baronciani
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

4.  Expression of the potent vasoconstrictor endothelin in the human central nervous system.

Authors:  M E Lee; S M de la Monte; S C Ng; K D Bloch; T Quertermous
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 5.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

6.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  Polymerase chain reaction amplification of two polymorphic simple repeat sequences within the von Willebrand factor gene: application to family studies in von Willebrand disease.

Authors:  A M Cumming; J G Armstrong; K Pendry; A M Burn; R T Wensley
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

8.  Genetic and blood coagulation characterization of "Swedish" families with von Willebrand's disease types I and III: new aspects of heredity.

Authors:  M Anvret; M Blombäck; M Lindstedt; E Söderlind; M Tapper-Persson; A C Thelander
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

9.  Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease.

Authors:  R B Levene; F M Booyse; J Chediak; T S Zimmerman; D M Livingston; D C Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

Review 10.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.